Dear Colleagues,

As we approach the Christmas holidays and prepare ourselves to welcome a fresh New Year, I take up the pleasurable task of connecting with you through this December 2014 edition of Oviya MedSafe’s newsletter. For Oviya MedSafe, 2014 was a year of significant progress and we are objectively confident that 2015 will be our year of significant expansion. Before writing more, let me pause to wish you and your families ‘Merry Christmas’ and ‘Happy New Year’!

First of all, I am exuberant to announce that Oviya MedSafe will be an exhibitor at the Drug Information Association’s Pharmacovigilance and Risk Management Strategies 2015 conference organized in Washington, DC, USA between January 26 and 28. With the North American market already being in our growth plan for early 2015, we at Oviya MedSafe see this as the best platform to proclaim our arrival. If you are attending this conference, please do visit us at Tabletop Number 16.

Oviya MedSafe’s USA expedition will also include business visits along the East Coast, specifically the states of New York, New Jersey & Pennsylvania. If you would like to pre-fix face-to-face meetings with our team, please feel free to contact us with your interests. In case you live in the above-mentioned states and wish to work for Oviya MedSafe, kindly let us know in advance so that we can try to set up interviews for you with our team during our visit.

On the home front, it is encouraging that a paradigm shift is happening in the drug regulatory system in India, with the CDSCO (Central Drugs Standard Control Organization) and the IPC (Indian Pharmacopoeia Commission) contemplating regulatory action following analysis of data collected through the PvPI (Pharmacovigilance Programme of India), thereby jointly committing to address the lacunae in the system.

The IPC’s commendable efforts in forming a signal review panel involving industry experts have paid off, with the panel’s report convincing the IPC to recommend issuance of advisory notes or label changes for certain medicines. This positive development stands testimony to the growing industry-government collaboration in Pharmacovigilance in the country.

The icing on the cake is that the Uppsala Monitoring Centre (UMC) has declared India to be the first country to report more than 100000 Individual Case Safety Reports (ICSRs) in VigiFlow and has agreed to train the PvPI staff on Signal Detection, as part of the deepening ties between the two organizations.

As these intriguing changes take place in India, the Pharmacovigilance Working Group of the Indian Society for Clinical Research (ISCR) has organized a symposium titled ‘Comprehensive Pharmacovigilance for India – The Road Ahead‘, at the right time. The symposium, which comprises eminent speakers from the industry, academia, PvPI, ICMR, Indian Medical Association and the clinical investigator community, will be held at Peninsula Grand Hotel, Andheri (East), Mumbai on Saturday 20-DEC-2014, between 8:30 AM and 5 PM. I feel privileged that I have been requested to be a speaker in this symposium, for the session titled ‘The Emergence and Promise of Pharmacovigilance as an Outsourced Industry in India – Perspectives from Service Providers’.

As this event brings together all stakeholders of pharmacovigilance on a single platform to discuss issues pertinent to India and jointly devise the way forward for the betterment of Indian Pharmacovigilance, I personally believe it will be an excellent opportunity for all of us to listen to various perspectives from different stakeholders and also share our opinions on the subject. As an Executive Committee Member of ISCR, I appeal to the pharmacovigilance fraternity in India to register for this symposium in large numbers and make it a grand success, which is sure to instigate higher levels of collaborations among all the stakeholders of Indian Pharmacovigilance.

Last but not the least, I wanted to share with you something that Oviya MedSafe is proud about: Our global headquarters Coimbatore which houses our global delivery centre, has been awarded India’s Best Emerging City at the India Today Best City Awards 2014. Apart from being declared the overall winner, Coimbatore has also scored the top rank among the emerging cities in the segments of Healthcare, Public Services, Transport and Investment. Subsequently, the Times of India too highlighted Coimbatore’s large pool of available talent and cost-effectiveness as its key advantages. I take this opportunity to invite you to visit Coimbatore and experience our zest and zeal, sometime soon!

I sign off with a big thanks to you for reading this long letter and with assurance of more interesting updates from Oviya MedSafe in January 2015!

Looking forward to meeting you at Mumbai & at Washington, DC,

With thanks & regards,
Dr J Vijay Venkatraman
MBBS, F. Diab., MBA., FPIPA (UK)

Managing Director & CEO, Oviya MedSafe
Pharmacovigilance Consulting & Drug Safety Services
Coimbatore, India & London, UK

India Office: +91-422-2444442
UK Office: +44-8452-733839

Leave a comment

Your email address will not be published. Required fields are marked *